Susan Kanaya Biography and Net Worth

CFO of ChemoCentryx

Susan M. Kanaya serves as Chief Financial Officer, Executive Vice President, Chief Administrative Officer, Secretary of the Company. Since February 2006. From January 2006 to October 2016, Ms. Kanaya served as our Senior Vice President, Finance, and Chief Financial Officer. Prior to joining us, Ms. Kanaya served as Senior Vice President, Finance, and Chief Financial Officer at Kosan Biosciences Inc., a biotechnology company, from 1999 to 2005. Prior to this, she served in financial management positions at SUGEN, Inc., a biotechnology company, from 1994 to 1999, most recently as Vice President, Finance, and Treasurer. Ms. Kanaya also served as Controller with high technology companies and as a public accountant with KPMG. Ms. Kanaya received her B.S. in business administration from the University of California, Berkeley.

What is Susan M. Kanaya's net worth?: The estimated net worth of Susan M. Kanaya is at least $4.75 million as of August 16th, 2022. Ms. Kanaya owns 91,317 shares of ChemoCentryx stock worth more than $4,747,571 as of April 4th. This net worth approximation does not reflect any other investments that Ms. Kanaya may own. Additionally, Ms. Kanaya receives a salary of $845,040.00 as CFO at ChemoCentryx. Learn More about Susan M. Kanaya's net worth.
How old is Susan M. Kanaya?: Ms. Kanaya is currently 59 years old. There are 4 older executives and no younger executives at ChemoCentryx. The oldest executive at ChemoCentryx is Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman, who is 63 years old. Learn More on Susan M. Kanaya's age.
What is Susan M. Kanaya's salary?: As the CFO of ChemoCentryx, Inc., Ms. Kanaya earns $845,040.00 per year. There are 2 executives that earn more than Ms. Kanaya. The highest earning executive at ChemoCentryx is Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman, who commands a salary of $1,210,000.00 per year. Learn More on Susan M. Kanaya's salary.
How do I contact Susan M. Kanaya?: The corporate mailing address for Ms. Kanaya and other ChemoCentryx executives is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. ChemoCentryx can also be reached via phone at (650) 210-2900 and via email at investor@chemocentryx.com. Learn More on Susan M. Kanaya's contact information.
Has Susan M. Kanaya been buying or selling shares of ChemoCentryx?: Susan M. Kanaya has not been actively trading shares of ChemoCentryx over the course of the past ninety days. Most recently, Susan M. Kanaya sold 19,898 shares of the business's stock in a transaction on Tuesday, August 16th. The shares were sold at an average price of $50.95, for a transaction totalling $1,013,803.10. Following the completion of the sale, the chief financial officer now directly owns 91,317 shares of the company's stock, valued at $4,652,601.15. Learn More on Susan M. Kanaya's trading history.
Who are ChemoCentryx's active insiders?: ChemoCentryx's insider roster includes Tausif Butt (COO), Markus Cappel (Treasurer), Thomas Edwards (Director), Susan Kanaya (CFO), Geoffrey Parker (Director), Thomas Schall (CEO), and James Tyree (Director). Learn More on ChemoCentryx's active insiders.

Susan M. Kanaya Insider Trading History at ChemoCentryx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/16/2022	Sell	19,898	$50.95	$1,013,803.10	91,317
8/4/2022	Sell	46,298	$50.17	$2,322,770.66	91,317
6/12/2020	Sell	50,000	$64.58	$3,229,000.00	121,317
5/5/2020	Sell	20,123	$54.73	$1,101,331.79	146,194
2/19/2020	Sell	24,200	$50.13	$1,213,146.00	91,317
2/13/2020	Sell	45,300	$49.61	$2,247,333.00	91,317
2/11/2020	Sell	3,000	$49.50	$148,500.00	91,317
1/17/2020	Sell	15,737	$41.03	$645,689.11	91,317
11/26/2019	Sell	311,625	$31.51	$9,819,303.75	162,931
3/27/2019	Sell	35,000	$13.05	$456,750.00	110,890
1/22/2019	Sell	37,893	$12.08	$457,747.44	110,746
6/28/2018	Sell	49,507	$13.79	$682,701.53	38,985
6/26/2018	Sell	850	$13.25	$11,262.50	38,985
5/15/2018	Sell	8,306	$11.14	$92,528.84	46,441
5/8/2018	Sell	65,328	$11.53	$753,231.84	103,463
5/2/2018	Sell	1,366	$11.50	$15,709.00	39,501
1/22/2016	Sell	25,764	$4.04	$104,086.56
1/20/2016	Sell	14,971	$4.10	$61,381.10
1/19/2016	Sell	6,134	$4.05	$24,842.70
1/15/2016	Sell	300	$4.00	$1,200.00
1/8/2016	Sell	10,224	$5.12	$52,346.88
1/6/2016	Sell	47,607	$6.98	$332,296.86
1/5/2016	Sell	34,341	$6.90	$236,952.90
1/4/2016	Sell	10,490	$7.38	$77,416.20
6/28/2013	Sell	36,942	$14.31	$528,640.02
5/30/2013	Sell	12,770	$14.28	$182,355.60
10/1/2012	Sell	3,971	$11.89	$47,215.19

See Full Table

Susan M. Kanaya Buying and Selling Activity at ChemoCentryx

ChemoCentryx Company Overview

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

Today's Range

Now: $51.99

$51.99

50 Day Range

MA: $51.95

$51.66

$51.99

2 Week Range

Now: $51.99

$14.95

$52.00

Volume

113 shs

Average Volume

1,681,906 shs

Market Capitalization

$3.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Susan Kanaya Biography and Net Worth

What is Susan M. Kanaya's net worth?

How old is Susan M. Kanaya?

What is Susan M. Kanaya's salary?

How do I contact Susan M. Kanaya?

Has Susan M. Kanaya been buying or selling shares of ChemoCentryx?

Who are ChemoCentryx's active insiders?